Osteosarcoma is a rare and aggressive form of bone cancer primarily affecting children and young adults with a prevalence of approximately 3.4 cases per million annually. It is often treated with a combination of surgery and chemotherapy, with first-line treatments including agents such as methotrexate, cisplatin, and doxorubicin. Despite these therapies, the disease presents a high unmet clinical need due to limited effectiveness in advanced stages and recurrences. The growing focus on targeted therapies, immunotherapy, and personalized medicine is likely to drive significant progress in the osteosarcoma drug pipeline in the coming years.
The Osteosarcoma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into osteosarcoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for osteosarcoma. The osteosarcoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The osteosarcoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with osteosarcoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to osteosarcoma.
Osteosarcoma is a malignant bone tumor that primarily affects adolescents and young adults, often occurring in long bones like the femur or tibia. It typically develops when abnormal cells grow uncontrollably, leading to aggressive bone destruction. With an incidence of about 3.4 cases per million people annually, the drug pipeline for osteosarcoma focuses on advanced treatments to improve survival rates and quality of life.
Osteosarcoma treatment involves surgery to remove the tumor, often combined with chemotherapy. First-line chemotherapy includes methotrexate, cisplatin, and doxorubicin. For recurrent or metastatic cases, targeted therapies and immunotherapy are being explored. Despite these options, the high risk of relapse highlights the need for more effective, personalized treatment strategies.
Osteosarcoma has an incidence of approximately 3.4 cases per million people annually, with a notable impact on younger populations. In the United States, there are around 440 cases yearly among individuals aged 0 to 19 years, estimating approximately 82 million in this age group. This rare but aggressive cancer highlights a critical unmet need, spurring advancements in targeted therapies and immunotherapies to improve treatment outcomes.
This section of the report covers the analysis of osteosarcoma drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total osteosarcoma clinical trials.
The drug molecule categories covered under the osteosarcoma pipeline analysis include small molecules, monoclonal antibodies, immunotherapies, gene therapies, and targeted therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for osteosarcoma.
The EMR osteosarcoma drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in osteosarcoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for osteosarcoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of osteosarcoma drug candidates.
The Phase II study, sponsored by Ipsen, aims to assess the efficacy, safety, and pharmacokinetics of maintenance cabozantinib plus best supportive care (BSC) versus BSC alone in children, adolescents, and young adults with unresectable residual osteosarcoma. The study is expected to be completed by June 2028, with an estimated 90 participants enrolled.
MedPacto, Inc., is sponsoring a study that aims to assess the safety, tolerability, and antitumor activity of Vactosertib in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. The Phase I/II study will evaluate the drug's efficacy and pharmacokinetics. The study, with around 48 participants enrolled, is expected to be completed by November 2025. The primary objective of the clinical trial is to determine the maximum tolerated dose and overall response rate.
The drug TQB2928 injection, combined with Anlotinib hydrochloride capsules, is sponsored by Chia Tai Tianqing Pharmaceutical Group and Nanjing Shunxin Pharmaceutical Co., Ltd. The objective of this Phase 1 study is to evaluate the efficacy and safety of the combination in patients with relapsed or metastatic osteosarcoma and other solid tumors. The study, enrolling about 43 participants, is expected to be completed by February 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Osteosarcoma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for osteosarcoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into osteosarcoma collaborations, regulatory environments, and potential growth opportunities.
Synovial Sarcoma Drug Pipeline Analysis Report
Global Cancer Gene Therapy Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share